Best Stocks Under $3 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $3.00 (3 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Ur Energy NYSEAMERICAN:URG$1.96 +0.04 (+1.81%) As of 01:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur EnergyMarket Capitalization$780.75 millionConsensus RatingBuyConsensus Price Target$2.57 (+30.6% Upside)Volume4.08 million sharesAverage Volume9.39 million sharesToday's Range$1.88▼$1.97 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. iBio NASDAQ:IBIO$1.92 +0.08 (+4.40%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. More about iBioMarket Capitalization$95.63 millionConsensus RatingBuyConsensus Price Target$4.75 (+147.3% Upside)Volume576,956 sharesAverage Volume1.38 million sharesToday's Range$1.83▼$2.003. Inhibikase Therapeutics NASDAQ:IKT$1.70 +0.03 (+1.50%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. More about Inhibikase TherapeuticsMarket Capitalization$223.79 millionConsensus RatingBuyConsensus Price Target$5.50 (+224.5% Upside)Volume142,107 sharesAverage Volume1.41 million sharesToday's Range$1.69▼$1.734. Stereotaxis NYSEAMERICAN:STXS$1.88 +0.04 (+2.23%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. More about StereotaxisMarket Capitalization$185.71 millionConsensus RatingBuyConsensus Price Target$3.88 (+106.0% Upside)Volume113,581 sharesAverage Volume462,376 sharesToday's Range$1.85▼$1.915. Peraso NASDAQ:PRSO$1.08 +0.02 (+1.42%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Peraso Inc, a fabless semiconductor company, develops, markets, and sells semiconductor devices and modules. The company's products include millimeter wavelength (mmWave) ICs, including baseband IC, various mmWave radio frequency, integrated circuits, as well as associated antenna technology; and mmWave antenna modules. More about PerasoMarket Capitalization$15.85 millionConsensus RatingBuyConsensus Price Target$3.00 (+179.1% Upside)Volume223,694 sharesAverage Volume5.34 million sharesToday's Range$1.04▼$1.096. Ovid Therapeutics NASDAQ:OVID$2.46 +0.08 (+3.14%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid TherapeuticsMarket Capitalization$460.07 millionConsensus RatingModerate BuyConsensus Price Target$5.13 (+107.9% Upside)Volume744,469 sharesAverage Volume2.47 million sharesToday's Range$2.42▼$2.527. Autolus Therapeutics NASDAQ:AUTL$1.68 +0.07 (+4.01%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus TherapeuticsMarket Capitalization$451.11 millionConsensus RatingModerate BuyConsensus Price Target$8.75 (+419.3% Upside)Volume859,708 sharesAverage Volume1.74 million sharesToday's Range$1.64▼$1.768. Palisade Bio NASDAQ:PALI$2.00 +0.07 (+3.37%) As of 01:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. More about Palisade BioMarket Capitalization$346.29 millionConsensus RatingModerate BuyConsensus Price Target$10.20 (+411.3% Upside)Volume1.02 million sharesAverage Volume4.06 million sharesToday's Range$1.89▼$2.069. Context Therapeutics NASDAQ:CNTX$2.12 +0.07 (+3.17%) As of 01:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$194.33 millionConsensus RatingModerate BuyConsensus Price Target$6.60 (+212.1% Upside)Volume250,696 sharesAverage Volume1.26 million sharesToday's Range$2.05▼$2.2310. Real Brokerage NASDAQ:REAX$1.62 +0.02 (+0.93%) As of 01:22 PM Eastern This is a fair market value price provided by Massive. Learn more.The Real Brokerage Inc, together with its subsidiaries, operates as a real estate technology company in the United States and Canada. More about Real BrokerageMarket Capitalization$346.94 millionConsensus RatingModerate BuyConsensus Price Target$5.69 (+250.0% Upside)Volume1.41 million sharesAverage Volume2.36 million sharesToday's Range$1.62▼$1.6811. Connect Biopharma NASDAQ:CNTB$2.28 +0.05 (+2.02%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. More about Connect BiopharmaMarket Capitalization$143.23 millionConsensus RatingModerate BuyConsensus Price Target$7.20 (+216.5% Upside)Volume254,151 sharesAverage Volume200,763 sharesToday's Range$2.25▼$2.3812. Compass Therapeutics NASDAQ:CMPX$2.12 +0.02 (+0.71%) As of 01:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. More about Compass TherapeuticsMarket Capitalization$382.33 millionConsensus RatingModerate BuyConsensus Price Target$12.91 (+510.4% Upside)Volume2.03 million sharesAverage Volume5.40 million sharesToday's Range$2.07▼$2.1813. Nouveau Monde Graphite NYSE:NMG$1.74 -0.06 (-3.06%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Nouveau Monde Graphite Inc engages in the acquisition, exploration, development, and evaluation of mineral properties in Quebec, Canada. More about Nouveau Monde GraphiteMarket Capitalization$280.65 millionConsensus RatingModerate BuyConsensus Price Target$4.67 (+167.4% Upside)Volume462,882 sharesAverage Volume1.09 million sharesToday's Range$1.72▼$1.8014. MediciNova NASDAQ:MNOV$1.32 +0.01 (+0.38%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. More about MediciNovaMarket Capitalization$65.22 millionConsensus RatingModerate BuyConsensus Price Target$7.50 (+466.0% Upside)Volume3,144 sharesAverage Volume53,961 sharesToday's Range$1.31▼$1.3315. Tenaya Therapeutics NASDAQ:TNYA$0.78 0.00 (-0.23%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya TherapeuticsMarket Capitalization$170.56 millionConsensus RatingModerate BuyConsensus Price Target$4.00 (+410.2% Upside)Volume1.51 million sharesAverage Volume4.29 million sharesToday's Range$0.78▼$0.8216. Nano-X Imaging NASDAQ:NNOX$2.04 +0.17 (+8.82%) As of 01:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. More about Nano-X ImagingMarket Capitalization$141.62 millionConsensus RatingModerate BuyConsensus Price Target$5.00 (+145.7% Upside)Volume1.24 million sharesAverage Volume1.27 million sharesToday's Range$1.84▼$2.1017. High Tide NASDAQ:HITI$2.39 +0.07 (+2.84%) As of 01:19 PM Eastern This is a fair market value price provided by Massive. Learn more.High Tide Inc engages in the cannabis retail business in Canada, the United States, and internationally. The company operates through Retail and Wholesale segments. More about High TideMarket Capitalization$209.99 millionConsensus RatingModerate BuyConsensus Price Target$6.13 (+156.7% Upside)Volume236,406 sharesAverage Volume440,956 sharesToday's Range$2.32▼$2.4318. Compugen NASDAQ:CGEN$2.22 +0.04 (+1.60%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. More about CompugenMarket Capitalization$210.37 millionP/E Ratio6.01Consensus RatingModerate BuyConsensus Price Target$5.00 (+124.7% Upside)Volume268,751 sharesAverage Volume456,698 shares19. Metagenomi NASDAQ:MGX$1.36 +0.04 (+2.63%) As of 01:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. More about MetagenomiMarket Capitalization$51.20 millionConsensus RatingModerate BuyConsensus Price Target$9.00 (+559.3% Upside)Volume72,982 sharesAverage Volume225,090 sharesToday's Range$1.30▼$1.3720. Nkarta NASDAQ:NKTX$2.76 +0.04 (+1.29%) As of 01:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More about NkartaMarket Capitalization$197.74 millionConsensus RatingModerate BuyConsensus Price Target$10.75 (+290.2% Upside)Volume220,867 sharesAverage Volume779,463 sharesToday's Range$2.69▼$2.8521. enCore Energy NASDAQ:EU$1.60 +0.03 (+1.58%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.enCore Energy Corp. engages in the acquisition, exploration, and development of uranium resource properties in the United States. More about enCore EnergyMarket Capitalization$311.74 millionConsensus RatingModerate BuyConsensus Price Target$3.83 (+138.8% Upside)Volume926,644 sharesAverage Volume3.02 million sharesToday's Range$1.57▼$1.6722. Senti Biosciences NASDAQ:SNTI$1.00 +0.02 (+2.02%) As of 01:19 PM Eastern This is a fair market value price provided by Massive. Learn more.Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. More about Senti BiosciencesMarket Capitalization$30.99 millionConsensus RatingModerate BuyConsensus Price Target$8.75 (+779.4% Upside)Volume95,879 sharesAverage Volume196,963 sharesToday's Range$0.96▼$1.0123. DeFi Technologies NASDAQ:DEFT$0.58 +0.02 (+3.02%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.DeFi Technologies, Inc engages in the provision of investment services. It plans to acquire equity, debt, or other securities of publicly traded or private companies or other entities. More about DeFi TechnologiesMarket Capitalization$226.62 millionP/E Ratio5.84Consensus RatingModerate BuyConsensus Price Target$2.00 (+242.5% Upside)Volume3.19 million sharesAverage Volume5.46 million shares24. American Resources NASDAQ:AREC$2.41 -0.05 (-1.99%) As of 01:22 PM Eastern This is a fair market value price provided by Massive. Learn more.American Resources Corporation, together with its subsidiaries, extracts, processes, transports, and sells metallurgical coal to the steel and industrial industries. More about American ResourcesMarket Capitalization$259.40 millionConsensus RatingModerate BuyConsensus Price Target$6.00 (+148.9% Upside)Volume1.19 million sharesAverage Volume3.62 million sharesToday's Range$2.34▼$2.4625. Humacyte NASDAQ:HUMA$1.48 +0.08 (+5.36%) As of 01:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. More about HumacyteMarket Capitalization$327.92 millionConsensus RatingModerate BuyConsensus Price Target$6.43 (+335.8% Upside)Volume4.20 million sharesAverage Volume6.59 million sharesToday's Range$1.38▼$1.51 More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker Ulta's Q1 Report Primes It for a Beauty of a Rebound Palo Alto Networks Accelerates Growth 31% on AI Demand How the Memory Shortage Is Crushing the Gaming Industry As AI Data Breaches Become More Common, This Cybersecurity ETF Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
